The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

In the case of myasthenia gravis, the body produces autoantibodies that target acetylcholine receptors (AChRs), which are essential triggers for normal muscle contraction functions. Medications ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

Neuphoria Therapeutics (NEUP) provided a review of 2024 and highlighted plans for 2025. “2024 and the first quarter of 2025 were ...